Egyptian study pits two liver cancer drug combos Head-to-Head
NCT ID NCT07669597
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks back at medical records of 50 adults in Egypt with advanced liver cancer who received one of two immunotherapy combinations: atezolizumab plus bevacizumab or durvalumab plus tremelimumab. Researchers want to see which group lives longer at 12 months and how they compare on tumor shrinkage, side effects, and quality of life. Because it uses past data, it can't prove cause and effect but may reveal real-world differences in Egyptian patients.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- atezolizumab plus bevacizumab; durvalumab plus tremelimumab
- What this could lead to
- If this study finds one regimen works better or is safer for Egyptian patients, it could help doctors choose the best first-line treatment for advanced liver cancer in that population.
- What could go wrong
- This is a small, retrospective study (only 50 patients) using existing records, so results may be less reliable than a large prospective trial. Differences in patient care or data quality could affect findings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 50 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Mar 2026
- Expected to finish
-
Jun 2027
An estimate. End dates often move.
- Lead sponsor
-
A government agency
The lead sponsor is a government body.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The study population includes adult patients aged 18 years or older with histologically or radiologically confirmed locally advanced or metastatic hepatocellular carcinoma who were treated at Suhag Cancer Center, Egypt. Eligible patients received either atezolizumab plus bevacizumab or durvalumab plus tremelimumab (STRIDE regimen) as first-line systemic therapy between January 2021 and December 2024. Patients must have ECOG performance status 0-1, disease not amenable to curative surgical or locoregional treatment, and at least one follow-up visit with complete clinical and radiologic records available.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age 18 of informed consent. * Laboratory and radiologically confirmed diagnosis of unresectable or metastatic hepatocellular carcinoma. * No prior systemic therapy for HCC. * Child-Pugh liver function class A (score 5-6). * ECOG performance status of 0 or 1. * Adequate haematologic and organ function as defined by: o Hemoglobin ≥ 9 g/dL o Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L o Platelets ≥ 75 × 10⁹/L o Serum creatinine ≤ 1.5 × ULN or creatinine clearance ≥ 50 mL/min o AST and ALT ≤ 5 × ULN (≤ 3 × ULN if no liver involvement) o ULN Total bilirubin ≤ 2 × 7. * Willingness to comply with study procedures and follow-up schedule. * Signed written informed consent obtained prior to any study-related procedures. Exclusion Criteria: * History of autoimmune disease requiring systemic immunosuppressive therapy. * Untreated or high-risk gastro-oesophageal varices as defined by institutional standards. * Prior liver transplantation or diagnosis of another active malignancy (excluding localized skin cancer or cervical carcinoma in situ) within the past three years. * Patients with high-risk oesophageal varices. * Patients with portal vein thrombosis. * Known HIV infection or active hepatitis B/C with uncontrolled viraemia. * Uncontrolled cardiovascular or thromboembolic disease (e.g., recent myocardial infarction, stroke, or pulmonary embolism within 6 months). * Active bleeding, coagulopathy, or platelet disorders contraindicating bevacizumab. * Lactation. * Pregnancy.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Locally advanced or metastatic hepatoceullar carcinoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sohag Oncology Center
Sohag, Egypt